Comparative Pharmacology
Head-to-head clinical analysis: CLOXAPEN versus GEOPEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLOXAPEN versus GEOPEN.
CLOXAPEN vs GEOPEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cloxapen inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically PBPs involved in the transpeptidation step of peptidoglycan cross-linking. It is resistant to staphylococcal beta-lactamases.
Carbenicillin is a bactericidal penicillin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has activity against Gram-negative and some Gram-positive bacteria.
Oral: 250-500 mg every 6 hours. IV: 1-2 g every 4-6 hours.
2 g intravenously every 6 hours for susceptible infections.
None Documented
None Documented
Terminal elimination half-life 1.5-2 hours; prolonged to 2.5-4 hours in severe renal impairment; clinical context: requires frequent dosing in normal renal function
Terminal half-life 4-6 hours in normal renal function; prolonged to 10-20 hours in moderate renal impairment (CrCl 10-50 mL/min) and up to 30-50 hours in severe impairment (CrCl <10 mL/min).
Renal 70-80% as unchanged drug and active metabolite; biliary 5-10%; fecal <5%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary/fecal: <2%.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic